




Ashutosh

29/10/2024 at 5:07 pm



Name : SUSHMA Age/Sex : 39YRS/F
Recpt No : 8035
Reported on : 26-Oct-24


S.NO: -8035 X-RAY CHEST PA

Bilateral lung fields are normal.
Bilateral costophrenic and cardiophrenic angles are clear.
Heart and mediastinum appear normal.

Impression: -

No significant abnormality is seen.

Please correlate clinically



DR. GLOSSY B SABHARWAL, MD
CONSULTANT RADIOLOGIST

Note: This is only a professional opinion and not the final diagnosis. Not valid for medico- legal purposes

TRADITION OF TRUST & CARE SINCE 1920

Patient Name : MRS. SUSHMA SRIVASTAVA Age / Gender : 39 years / Female MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : SELF		Registration Time : Oct 26, 2024, 03:37 p.m. Receiving Time : Oct 26, 2024, 04:31 p.m. Reporting Time : Oct 26, 2024, 04:41 p.m.  241026150 Panel : SELF Client Code : DIRECT
--	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

IMMUNOLOGY

Anti Mullerian Hormone,Serum

AMH Anti Mullerian Inhibiting Substance	1.84	ng/mL	
Method : ECLIA			

For biological reference interval, please refer to the table given below.

Adult Females	
Age Range (year)	AMH Biological ref interval in ng/ml
20 - 24	1.52 - 9.95
25 - 29	1.20 - 9.05
30 - 34	0.711 - 7.59
35 - 39	0.405 - 6.96
40 - 44	0.059 - 4.44
45 - 50	0.010 - 1.79
PCOS Women	2.41 - 17.1
Adult Males	1.43 - 11.6

Comments:

Antimullerian hormone (AMH), also known as mullerian-inhibiting substance, is a dimeric glycoprotein hormone belonging to the transforming growth factor-beta family. It is produced by sertoli cells of the testis in males and by ovarian granulosa cells in females. In women, antimullerian hormone (AMH) levels represent the ovarian follicular pool and could be a useful marker of ovarian reserve. A serum level of AMH strongly correlates with antral follicle count and reflect the size of primordial follicle pool thus may be useful as a predictor of ovarian responsiveness. AMH may permit the identification of both the extremes of ovarian stimulation thus a possible role for its measurement has been suggested in the individualization of treatment strategies.

Clinical Applications *


Patient Name : MRS. SUSHMA SRIVASTAVA Age / Gender : 39 years / Female MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : SELF		Registration Time : Oct 26, 2024, 03:37 p.m. Receiving Time : Oct 26, 2024, 04:31 p.m. Reporting Time : Oct 26, 2024, 04:41 p.m.  241026150 Panel : SELF Client Code : DIRECT
--	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

To assess ovarian status including follicle development, ovarian reserve, and ovarian responsiveness, as part of evaluation for infertility and assisted reproduction protocols.

- * To assess menopausal status, including premature ovarian failure.
- * To assess ovarian function in patients with polycystic ovarian syndrome.
- * To evaluate infants with ambiguous genitalia and other intersex conditions
- * To evaluate testicular function in infants and children.■
- * To diagnose and monitor patients with antimullerian hormone-secreting ovarian granulosa cell tumors.

END OF REPORT



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MRS. SUSHMA SRIVASTAVA Age / Gender : 39 years / Female MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : .		Registration Time : Oct 26, 2024, 10:49 a.m. Receiving Time : Oct 26, 2024, 10:50 a.m. Reporting Time : Oct 26, 2024, 01:48 p.m.  241026083 Panel : SELF Client Code : DIRECT
---	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

SEROLOGY


HIV (spot),Serum

HIV 1 & 2 Antibodies Screening Test, Serum Method : Immunochromatography	Non- Reactive		Non Reactive
---	---------------	--	--------------

Note

- All reactive samples are tested by 3 different methods as per NACO guidelines, 2010.
- The test results obtained relate only to the sample given or recieved.

END OF REPORT



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MRS. SUSHMA SRIVASTAVA Age / Gender : 39 years / Female MR No. / IPD No. : / Patient Type / Bed No. : / / Referred By : .		Registration Time : Oct 26, 2024, 10:49 a.m. Receiving Time : Oct 26, 2024, 10:50 a.m. Reporting Time : Oct 26, 2024, 01:48 p.m.  241026083 Panel : SELF Client Code : DIRECT
---	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

SEROLOGY

HBsAg (spot),Serum


Hepatitis B Surface Antigen (HBSAg)-Rapid Screening Non Reactive Non Reactive

Method : Immunochromatography

Remark:

All Reactive results must be confirmed by Neutralizing confirmatory test or by HBV DNA detection assay.

END OF REPORT



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MRS. SUSHMA SRIVASTAVA		Registration Time : Oct 26, 2024, 10:49 a.m.
Age / Gender : 39 years / Female		Receiving Time : Oct 26, 2024, 10:50 a.m.
MR No. / IPD No. : /		Reporting Time : Oct 26, 2024, 01:48 p.m.
Patient Type / Bed No. : /		 241026083
Referred By : .		Panel : SELF
		Client Code : DIRECT

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

SEROLOGY


HCV (spot),Serum

Anti HCV Antibody (HCV) Rapid Screening Test Non- Reactive Non Reactive
 Method : Immunofiltration

Note:

This is a screening test. All positive tests must be reconfirmed and the samples should be submitted further for more specific tests like viral detection by PCR.

END OF REPORT


Dr. Arti Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012

Patient Name : MRS. SUSHMA SRIVASTAVA		Registration Time : Oct 26, 2024, 10:49 a.m.
Age / Gender : 39 years / Female		Receiving Time : Oct 26, 2024, 10:50 a.m.
MR No. / IPD No. : /		Reporting Time : Oct 26, 2024, 03:28 p.m.
Patient Type / Bed No. : /		 241026083
Referred By : .		Panel : SELF
		Client Code : DIRECT

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

IMMUNOLOGY

Prolactin,Serum

Prolactin	7.24	ng/mL	4.79 - 23.30
------------------	------	-------	--------------

Method : CLIA

Interpretation:

Useful for Aiding in evaluation of pituitary tumors, amenorrhea, galactorrhea, infertility, and hypogonadism and monitoring therapy of prolactin-producing tumors.

In normal individuals, prolactin concentrations increase in response to physiologic stimuli such as sleep, stress, exercise and hypoglycemia, and are also elevated during pregnancy, lactation, postpartum, and in the newborn infant.

In patients with asymptomatic hyperprolactinemia, assessment for Macroprolactin (prolactin bound to immunoglobulin) is suggested.

Prolactin levels will vary over a 24-hour period, rising during sleep and peaking in the early morning.

Limitations: Moderately increased concentrations of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary adenoma is present.

Certain medications can cause increased Prolactin level.

END OF REPORT



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MRS. SUSHMA SRIVASTAVA Age / Gender : 39 years / Female MR No. / IPD No. : / Patient Type / Bed No. : / / Referred By : .		Registration Time : Oct 26, 2024, 10:49 a.m. Receiving Time : Oct 26, 2024, 10:50 a.m. Reporting Time : Oct 26, 2024, 01:51 p.m.  241026083 Panel : SELF Client Code : DIRECT
---	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

HAEMATOLOGY

Electrophoresis - Haemoglobin(HPLC)

Haemoglobin (Hb)	12.6	gm/dL	12-15
<small>Method : SLS-hemoglobin</small>			
RBC count	4.37	Millions/cumm	3.8-4.8
<small>Method : hydrodynamically focused DC detection</small>			
MCV	89.5	fL	80-100
<small>Method : Calculated</small>			
MCH	28.8	pg	27-32
<small>Method : Calculated</small>			
RDW CV	14.3	%	11.5-14.5
<small>Method : Calculated</small>			
HbA0 Level	84.4	%	-
<small>Method : HPLC</small>			
HbA2	3.1	%	1.5 - 3.5
<small>Method : HPLC</small>			
HbF(Fetal)	<0.8	%	0-2.0
<small>Method : HPLC</small>			

Comment:

Suggestive of absence of beta thalassemia trait & absence of common abnormal hemoglobin


Interpretation:

1. All results have to be correlated with age and history of blood transfusion If there is history of blood transfusion in last 3 months, repeat testing after 3 months from last date of transfusion is recommended.
2. Confirmation of diagnosis must be done in conjunction with Parental Screening, DNA study and blood picture. B12 & Serum Iron studies to be done if deemed necessary.
3. Megaloblastic anemia can result in high Hb A2. The Hb A2 results must be repeated after correcting the B12 deficiency
4. Severe Iron deficiency can lead to borderline Hb A2's. The HbA2 results must be repeated after correcting the iron deficiency.
5. Family studies must be done to confirm the compound heterozygous conditions of thalassemia and a hemoglobinopathy together or when two hemoglobinopathies coexist
6. Some hemoglobin variants are clinically silent. In case of normal interpretation silent carrier testing was not included.

END OF REPORT

Patient Name : MRS. SUSHMA SRIVASTAVA Age / Gender : 39 years / Female MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : .		Registration Time : Oct 26, 2024, 10:49 a.m. Receiving Time : Oct 26, 2024, 10:50 a.m. Reporting Time : Oct 26, 2024, 01:51 p.m.  241026083 Panel : SELF Client Code : DIRECT
---	---	---


Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient report

Bio-Rad DATE: 10/26/2024
 D-10 TIME: 12:52 PM
 S/N: #DJ23B12802 Software version: 4.30-2
 Sample ID: 241026083
 Injection date 10/26/2024 12:48 PM
 Injection #: 11 Method: HbA2/F
 Rack #: --- Rack position: 3



Peak table - ID: 241026083

Peak	R.time	Height	Area	Area %
A1a	0.20	9249	42355	1.3
A1b	0.28	8285	30274	0.9
F	0.46	3167	21917	< 0.8 *
LA1c/CHb-1	0.66	4948	40517	1.2
A1c	0.85	11548	122239	5.4
P3	1.50	19409	157706	4.8
A0	1.69	576564	2768605	84.4
A2	3.23	4962	96453	3.1
Total Area:			3280064	

Concentration:	%
F	< 0.8 *
A1c	5.4
A2	3.1



Name	: Mrs.SUSHMA SRIVASTAVA	Centre Details	:MALVIN DIAGNOSTICS
Age	: 39 Yrs Sex: Female	Accession.ID	:SDL2410260059
Collection Date	: 26/Oct/2024 02:12PM	Referred By	:DR GYNAE UNIT
Received Date	: 27/Oct/2024 09:23AM	Report Date	:29/Oct/2024 04:19PM
Registration Date	: 26/Oct/2024	Ref.No/TRF.No	: /

DEPARTMENT OF CYTOLOGY

Conventional PAP Smear Smear

SPECIMEN DETAILS :

LAB. NO. : C/5993/24

Conventional PAP smear
One unstained smear.

CLINICAL DETAILS:

P/S Cervix hypertrophic cyst.
LMP : 23/10/24

REPORTING MODE :

By Bethesda System 2014

ADEQUACY:

Satisfactory for evaluation.
Endocervical/transformation zone component present.

MICROSCOPY :

Smear shows many intermediate cells, superficial squamous cells and moderate number of neutrophils.

IMPRESSION :

Negative for any intraepithelial lesion or malignancy.

DISCLAIMER

Gynaecological cytology is a screening test that aids in the detection of cervical cancer and cancer precursors. Both false positive and false negative results can occur. The test should be used at regular intervals, and positive results should be confirmed before definitive therapy.

***** End Of Report *****

Disclaimer: All Results released pertain to the specimen submitted to the lab 1. Test results are dependent on the quality of the sample received by the lab 2. Tests are performed as per schedule given in the test listing and in any unforeseen circumstances, report delivery may be delayed 3. Test results may show interlaboratory variations 4. All dispute and claims are subjected to local jurisdiction only. Clinical correlation advised. 5. Test results are not valid for medico legal purposes 6. For all queries, feedbacks, suggestions, and complaints, please contact customer care support +0124 665 0000



Deepthi

Dr. Deepthi Gupta
MBBS, MD, Pathology
Consultant Surgical Pathology
DMC RG No. 52618